NeurOrbis Ventures LLC
AI-Powered Technology Ecosystem Intelligence

Understand an Entire Technology Landscape.
Make Better Decisions. Faster.

Explore patents, scientific literature, clinical trials, companies, market intelligence, licensing, and news—all through one AI-powered platform built for your technology domain.

Explore Intelligence PlatformsWatch Platform Tour

Purpose-built intelligence platforms for high-impact technology domains.

Drug Discovery & Therapeutics
Batteries
Artificial Intelligence
Biotechnology
Advanced Materials

Built for R&D, IP and Innovation Teams

Neurorbis
Featured Platform: GLP-1 Ecosystem Intelligence
Patents Tracked
16,500
+12% this quarter
Active Trials
312
+4% this quarter
Companies
204
-2% this quarter
Patent Filing Momentum
Trailing 12 months
+18.4%
AI Assistant
3 companies filed oral-delivery patents in the last 6 months...
PatentsLiterature

Technology Intelligence Platforms

Featured Platform

GLP-1 Ecosystem Intelligence

The most comprehensive intelligence platform for the incretin (GLP-1) space.

  • Patent Landscape and Analytics
  • Scientific Literature Intelligence
  • Clinical Trials & Drug Pipeline
  • Company & Competitive Intelligence
  • Licensing & Deal Tracking
  • Market Intelligence & Forecasts
  • Regulatory & News Monitoring
  • AI Assistant for Deep Intelligence
Explore GLP-1 PlatformView Sample Report
neurorbis.com/platforms/glp-1
Overview
Patents
Literature
Trials
Companies
1,240
86

Solid-State Battery Intelligence

Next-gen energy storage patents, chemistry and manufacturing scale-up.

AI in Drug Discovery Intelligence

Machine learning pipelines reshaping therapeutic discovery.

Custom Technology Intelligence

A dedicated platform built around your organization's domain.

• Why Neurorbis •

From Fragmented Research to
Connected Intelligence

NeurOrbis unifies the world's most critical intelligence sources and transforms disconnected data into insights that drive better decisions, faster.

Without Neurorbis

Fragmented. Manual. Time-consuming.

!
!
!
!
!
!
Patent Databases
Scientific Literature
Market Reports
Clinical Trials
Company Information
Spreadsheets & Files
News & Updates
Your Team
Data silos and disconnected sources
Outdated reports and stale insights
Manual searching across multiple tools
Hard to see the full technology picture
Neurorbis
With Neurorbis

Connected. AI-Powered. Always Current.

Patents
25,418
Publications
18,342
Clinical Trials
2,193
Companies
6,842
Technology Trend Over Time
201920202021202220232024
Top Companies by Activity
NeuroShield
MedNova
AutoSense
BioNova AI Systems
BioForge Insights
Technology Map
Recent Insights
New GLP-1 receptor patent cluster shows acceleration in oral delivery.
Neurocompounds are expanding in oral peptide delivery formulations.
Clinical trials for combination therapies are rising across markets.
View all insights →
Unified Intelligence
Everything connected in one platform.
AI-Powered Discovery
Ask questions. Get answers. Uncover what matters.
Expert-Curated
Domain-specific taxonomies and tagging for accuracy
Always Current
Continuous updates across all sources
Built for Teams
Collaborate, annotate and make aligned decisions
360° Technology View
See the full innovation landscape and make strategic moves
Turn information into intelligence. Make decisions with confidence.
Explore the Platform
Want to see how NeurOrbis works for your team?
Request a Demo
AI-Powered Research Assistant

Ask Your Technology Anything

Explore patents, scientific literature, clinical trials, market intelligence, companies, licensing, and news through one AI-powered research assistant. Every answer is connected to its supporting evidence.

Ask a question about any technology...

Try these questions

Data Sources

PatentsScientific LiteratureClinical TrialsCompanies & LicensingMarket IntelligenceNews & Regulatory
Secure. Private. Enterprise-ready.
AI Insight
Today, 10:24 AM

Several companies are actively developing oral GLP-1 therapies. Novo Nordisk currently leads with commercialized oral semaglutide, while Eli Lilly, Pfizer and Structure Therapeutics are exploring differentiated approaches.

Recent patent filings indicate increasing activity around oral delivery technologies, absorption enhancers and combination therapies.

Patent Insight
Recent filings focus on oral peptide stabilization and absorption enhancers.
124 Patents
Scientific Evidence
Novel carrier systems and permeability enhancers.
86 Publications
Clinical Evidence
Multiple Phase III trials evaluating oral GLP-1 therapies.
42 Clinical Trials
Company & Licensing
Strategic partnerships and licensing activity.
31 Companies / Deals
Market Perspective
Growing commercial adoption and expansion.
18 Market Reports
News & Regulatory
Recent approvals and regulatory milestones.
12 News Items

Evidence Mix

Patents: 39%Scientific Literature: 27%Clinical Trials: 13%Companies & Licensing: 10%Market Intelligence: 7%News & Regulatory: 4%
313Total Sources
Patents39%
Scientific Literature27%
Clinical Trials13%
Companies & Licensing10%
Market Intelligence7%
News & Regulatory4%
Confidence Level
High

Generated using evidence from six connected intelligence sources.

Answers are generated using connected intelligence across multiple data sources.
Every insight is traceable to its supporting evidence.

Explore AI Research Assistant
120M+
Patent Records
80%
Cost Reduction
6
Intelligence Domains
75%
Faster Research
Start your intelligence journey

Stop guessing.
Start knowing.

Get a personalised 15-minute walkthrough of Neurorbis — built around your team's technology domain, research priorities, and IP strategy.

Book a 15-Min WalkthroughExplore Reports
Trusted by R&D & IP Teams75% Faster DecisionsEnterprise-Grade SecurityGlobal Patent Coverage